迪哲医药筹划赴港二次IPO：前三季度营收增73%未盈利，A股市值268亿元

Group 1 - The company plans to issue overseas listed foreign shares (H-shares) and list on the Hong Kong Stock Exchange to enhance its global strategy and brand image [2] - The company aims to consider the interests of existing shareholders and market conditions when deciding the timing and window for the issuance within 24 months of shareholder approval [2] - The company is an innovative biopharmaceutical firm focused on research, development, and commercialization of therapies for malignant tumors and immune diseases [2] Group 2 - For the first three quarters of 2025, the company reported revenue of 586 million yuan, a year-on-year increase of 73.23% [2] - The net profit attributable to shareholders was -580 million yuan, compared to -558 million yuan in the same period last year [2] - The company reported a total revenue of approximately 231 million yuan for the current reporting period, reflecting a 71.46% increase year-on-year [3]